| ATC code J: Antiinfectives for systemic use | 
|---|
  | 
| Human only | 
| ATCvet only | 
  | 
| Other ATC codes | 
ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
See also
- Immune sera, immunoglobulins and vaccines for veterinary use are in the ATCvet group QI.
 
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
 - ↑ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
 - ↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
 - ↑ "ATC/DDD Index 2022: code J". WHO Collaborating Centre for Drug Statistics Methodology.
 - ↑ "ATCvet Index 2022: code QJ". WHO Collaborating Centre for Drug Statistics Methodology.
 
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System  | |
|---|---|
| gastrointestinal tract / metabolism (A)  | |
| blood and blood forming organs (B)  | |
| cardiovascular system (C)  | |
| skin (D) | |
| genitourinary system (G)  | |
| endocrine system (H)  | |
| infections and infestations (J, P, QI)  | |
| malignant disease (L01–L02)  | |
| immune disease (L03–L04)  | |
| muscles, bones, and joints (M)  | |
| brain and nervous system (N)  | 
  | 
| respiratory system (R)  | |
| sensory organs (S) | |
| other ATC (V) | |
  | |
| 30S | 
  | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50S | |||||||||||||||
| EF-G | 
  | ||||||||||||||
  | |||||||||||||||
| Beta-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases)  | 
  | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polypeptides | 
  | ||||||||||||||||||||||||||||||||||||||||||
| Intracellular | 
  | ||||||||||||||||||||||||||||||||||||||||||
| Other | 
  | ||||||||||||||||||||||||||||||||||||||||||
  | |||||||||||||||||||||||||||||||||||||||||||
| Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis)  | 
  | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication)  | 
  | ||||||||||||||||
| Anaerobic DNA inhibitors  | 
  | ||||||||||||||||
| RNA synthesis | 
  | ||||||||||||||||
  | |||||||||||||||||
| Other/ungrouped | |
|---|---|
| Wall/ membrane  | 
  | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular | 
  | ||||||||||||||||||||||
| Others | 
  | ||||||||||||||||||||||
  | |||||||||||||||||||||||
| Nucleic acid inhibitor | 
  | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein synthesis inhibitor | 
  | ||||||||
| Cell envelope antibiotic | 
  | ||||||||
| Other/unknown | |||||||||
| Combinations | |||||||||
  | |||||||||
| Baltimore I | 
  | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatitis B (VII) | |||||||||||||||||||||
| Multiple/general | 
  | ||||||||||||||||||||
  | |||||||||||||||||||||
| Hepatitis C | 
  | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general | 
  | ||||||||
  | |||||||||
| Capsid inhibitors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entry/fusion inhibitors  (Discovery and development)  | |||||||||||||
| Integrase inhibitors (Integrase strand transfer inhibitors (INSTI))  | |||||||||||||
| Maturation inhibitors | |||||||||||||
| Protease Inhibitors (PI) (Discovery and development)  | 
  | ||||||||||||
| Reverse-transcriptase inhibitors (RTIs)  | 
  | ||||||||||||
| Combined formulations | 
  | ||||||||||||
| Pharmacokinetic boosters | |||||||||||||
| Experimental agents | 
  | ||||||||||||
  | |||||||||||||
Immune sera and immunoglobulins (J06)  | |||||
|---|---|---|---|---|---|
| Polyclonal antibodies | 
  | ||||
| Monoclonal antibodies | |||||
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines | 
  | ||||||||||
| Inventors/ researchers  | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
  | |||||||||||
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.